Bromelain
Of 2,972 on-market bromelain products in the January 2026 DSLD dump, the median declared dose is 60 mg, and 100.0% list unspecified/undisclosed form as the primary form.
Form share
Of 2,959 products with an identifiable primary form, here is the share held by each form of Bromelain on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| unspecified/undisclosed form | Unrated | 2,959 | 100.0% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 1,391 products with a disclosed amount.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 36.4% of products fall below the fairy-dust threshold (40 mg, 20% of the studied low dose).
- 46.0% of products don't disclose an amount because Bromelain is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mg) to see exactly how it compares to the 1,391 on-market bromelain products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for bromelain on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Label discloses bromelain mass without a source part (fruit vs stem) or enzyme-activity grade; no verified human study compares grades or sources.
Reference values
- RDA (adult): not established — Proteolytic enzyme mixture from pineapple; not a nutrient, no RDA/AI exists.
- Tolerable Upper Intake Level (adult): not established — Not established. A systematic review and meta-analysis of bromelain trials reported flatulence, nausea and headache as adverse events and no major health risks during treatment (Leelakanok N et al. 2023, Nutr Health 29(3):479-503, PMID 37157782); a separate systematic review reported mainly mild gastrointestinal effects (Pereira IC et al. 2023, PMID 37202035). Trial observations, not an upper limit.
- Studied clinical dose range: 200–1050 mg
- Pereira IC et al. 2023, Clin Nutr ESPEN 55:116-127, PMID 37202035 -- systematic review of 7 RCTs of bromelain and inflammatory markers; in the studies of bromelain given alone (not combined) doses ranged 200-1050 mg/day for 1 to 16 weeks; the review judged the overall effect on inflammation inconsistent between studies. Pain context: Leelakanok N et al. 2023, PMID 37157782 -- meta-analysis in which oral bromelain gave slightly but significantly lower pain scores than controls (mean difference -0.27, 95% CI -0.45 to -0.08, n=9).
- Note: Unit basis: mg of bromelain powder as declared. Enzyme potency (GDU - gelatin digesting units, or MCU - milk clotting units, per gram) is the meaningful strength and varies several-fold between products (raw_form text includes "2400 GDU/g", "1200 GDU" and "300 GDU"), so equal mg is not equal activity; labels that declare activity units instead of mass (unit "GDU") are unit-flagged by the pipeline and excluded from dose metrics. The trial abstracts above do not state activity, so the studied range is mg of product of unspecified potency.